Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Caught Surprised By Outcomes For Two Key Products

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)

You may also be interested in...

Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave

The Contrave "complete response" letter could mean research in the category is sidelined now that all three of the current obesity drug candidates have been rejected.

Full Data For Seattle Genetics’ Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates

Seattle Genetics and partner Takeda are revising their regulatory strategy and will file their antibody drug conjugate SGN-35 in the first quarter of 2011 for both Hodgkin's lymphoma and anaplastic large cell lymphoma, following a positive reception for their pivotal data at the American Society of Hematology annual meeting.

Takeda Bulks Up In Obesity With Orexigen Deal

Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts